Editorial Central & Peripheral Nervous Systems: Dopamine D₁ receptor agonists and dopamine reuptake blockers: new treatment stratagems for Parkinson's disease

References

• STRANGE P: Dopamine receptors in the basal ganglia:relevance to Parkinson's disease. Mov. Disord. (1993) 8:263–270.
   PubMed Web of Science ®Google Scholar
• BLANCHETTE P, BEDARD PJ, MATSUMURA M, RICHARD H,FILION M: Pathophysiology of levodopa-induced dyski-nesia: concepts. In: The Basal Ganglia IV. Percheron et al, (Eds.), York (1994):539–548.
   Google Scholar
• BOYCE S, RUPNIAK NMJ, STEVENTON MJ, IVERSEN SD:Differential effects of Di and D2agonists in MPTP-treated primates: functional implications for Parkinson's dis-ease. Neurology (1990) 40:927–933.
   PubMedGoogle Scholar
• CLOSE SP, MARRIOTT AS, PAY S: Failure of SKF 38393-A to relieve parkinsonian symptoms induced by MIYIP in the marmoset. Br. J. Pharmacol. (1985) 85.320–322.
   PubMedGoogle Scholar
• FALARDEAU P, BOUCHARD S, BEDARD PJ, BOUCHER R, DI PAOLO T: Behavioural and biochemical effect of chronic treatment with 1)-1 and/or D-2 dopamine agonists in MPTP monkeys. Eur. J. Pharmacol. (1988) 150:59–66.
   PubMedGoogle Scholar
• LOSCHMANN P-A, SMITH LA, LANGE KW et al.: Motor activity following the administration of selective Di and D2 dopaminergic drugs to MPLP-treated common mar-mosets. Psychopharmacology (1992) 109:49–56.
   PubMedGoogle Scholar
• NOMOTO M, JENNER P, MARSDEN CD: The Di agonist SKF 38393 inhibits the antiparkinsonian activity of the D2 agonist LY 171555 in the MPIP-treated marmoset. Neurosci. Lett. (1988) 93:275–280.
   PubMedGoogle Scholar
• NOMOTO M, FUKUDA T: The effects of Di and D2dopamine receptor agonists and antagonists on Park-insonism in chronic MPTP-treated monkeys. In: Ad-vances in Neurology. Narabayashi H, Nagatsu T, Yanagisawa N, Mizuno Y (Eds.), Raven Press, New York (1993) 60:119–122.
   Google Scholar
• BRAUN A, FABBRINI G, MOURADIAN MM et al.: Selective Di dopamine receptor agonist treatment of Parkins on's disease. J. Neural. Transm. (1987) 68:41–50.
   PubMed Web of Science ®Google Scholar
• PIFL C, FtEITHER H, HORNYKIEWICZ 0: Lower efficacy of the dopamine Di agonist, SKF 38393, to stimulate adenylyl cyclase activity in primate than in rodent striatum. Eur.J. Pharmacol. (1991) 202:273–276.
   PubMedGoogle Scholar
• BEDARD PJ, GOMEZ-MANCILLA B, BLANCHETTE P et al.: Role of selective Di and Di agonists in inducing dyski-nesia in drug-naive MPTP monkeys. In: Advances in Neurology. Narabayashi H, Nagatsu T. Yanagisawa N, Mizuno Y, (Eds.), Raven Press, New York (1993) 60:113–118.
   Google Scholar
• BLANCHET P, BEDARD PJ, BRrfTON DR, KEBABIAN JAW: Differential effect of selective Di and Di dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-expos ed monkeys. J. Pharmacol. Exp. Ther. (1993) 267:275–279.
   PubMed Web of Science ®Google Scholar
• BLANCHET PJ, GRONDIN R, BEDARD PJ: Dyskinesia and wearing-off following dopamine Di agonist treatment in drug-naive 1-methy1-4-pheny1-1,2,3,6-tetrahy-dropyridine-lesioned primates. Mov. Disord. (1996) 11:91–94.
   PubMedGoogle Scholar
• DOMINO EF, SFIENG J: Relative potency and efficacy ofsome dopamine agonists with varying selectivities for Di and 132 receptors in MPTP-induced hemiparkin-sonian monkeys. J. Pharmacol. Exp. Ther. (1993) 265:135–136.
   Google Scholar
• GNANALINGHAM KK, EROL DD, HUNTER AJ et al.: Differ-ential anti-parkinsonian effects of benzazepine Di dopamine agonists with varying efficacies in the M1v113-treated common marmoset. Psychopharmacology (1995) 117:275–286.
   PubMedGoogle Scholar
• GNANALINGHAM KK, HUNTER AJ, JENNER P, MARSDENCD: Selective dopamine antagonist pretreatment on the antiparkinsonian effects of benzazepine Di dopasnine agonists in rodent and primate models of Parkinson's disease - the differential effects of Di dopamine antago-nists in the primate. Psychopharmacology (1995) 117:403–412.
   PubMedGoogle Scholar
• KEBABIAN JW, BRITTON DR, DENINNO MP et al.: A-77636:a potent and selective dopamine Di receptor agonist with antiparkinsonian activity in marmosets. Euro J. Pharmacol. (1992) 229:203–209.
   PubMed Web of Science ®Google Scholar
• PEARCE RKB, JACKSON M, SMITH L, JENNER P, MARSDENCD: Chronic L-DOPA administration induces dyskine-sias in the MPTP-treated common marmoset (Callithrix jacchus). Mov. Disord. (1995) 10:731–740.
   PubMedGoogle Scholar
• PEARCE RKB, BRITTON DR, SHIOSAKI K, JENNER P, MARS-DEN CD: Actions of the Di agonist A-77636 upon L-DOPA-induced dyskinesias in the MPTP-treated common marmoset. Mov. Disord. (1994) 9\(Suppl. 1):611.
   Google Scholar
• RUPNIAK NMJ, BOYCE S, STEVENTON M, IVERSEN SD: Weak antiparkinsonian activity of the Di agonist C-ABP (SKF 82958) and lack of synergism with a Di agonist in primates. din. Neuropharmacol. (1992) 15:307–309.
   Google Scholar
• SHIOSAKI K, JENNER P, ASIN KE et al.: ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine Di receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease. J. Pharmacol. Exp. Ther. (1996) 276:150–160.
   PubMed Web of Science ®Google Scholar
• TAYLOR JR, LAWRENCE MS, RECLMOND DE et al.: Di-hydrexidine, a full dopamine Di agonist, reduces MPTP-induced parkinsonism in monkeys. Eur. J. Pharmacol. (1991) 199:389–391.
   PubMedGoogle Scholar
• TEMLETT JA, QUINN NP, JENNER PG et al.: Anti-parkin-sonian activity of CY 208-243, a partial Di dopamine agonist, in MPTP-treated marmosets and patients with Parkinson's disease. Mov. Disord. (1989) 4:262–265
   Google Scholar
• VERMEULEN RJ, DRUKARCH B, SAHADAT MCR et al.: The selective dopamine Di receptor agonist, SKF 81297, stimulates motor behavior of MPTP-lesioned monkeys. Eur.J. Pharmacol. (1993) 235:144–147.
   Google Scholar
• EMRE M, RINNE UK, RASCOL A et al.: Effects of a selective partial Di agonist, CY 208-243, in de novo patients with Parkinson's disease. Mov. Disord. (1992) 7:239–243.
   PubMedGoogle Scholar
• TSUI JKC, WOLTERS EC, PEPPARD RF, CAINE DB: A double blind placebo-controlled, dose ranging study to inves-tigate the safety and efficacy of CY 208-243 in patients with Parkinson's disease. Neurology (1989) 39:856–858.
   PubMedGoogle Scholar
• WAITERS JR, BERGSTROM DA, CARLSSON 311 et aZ: Di dopamine receptor activation required for postsynap-tic expression of D2 agonists effects. Science (1987) 236:719–722.
   PubMedGoogle Scholar
• VERMEULEN RJ, DRUKARCH B, SAHADAT MCR et at: Thedopamine Di agonist SKF 81297 and the dopamine Di agonist LY 17155 act synergistically to stimulate motor behavior of 1-methy1-4-pheny1-1,2,3,6-tetrahy-dropyridine-lesioned parkinsonian rhesus monkeys. Mov. Disord. (1994) 9:664–672.
   PubMedGoogle Scholar
• ROBERTSON HA, PETERSON MR, WORTH GG: Synergisticand persistent interaction between the Di agonist bro-mocriptine, and the Di selective agonist, CY 208-243. Brain Res. (1992) 593:332–334.
   PubMedGoogle Scholar
• GERFEN CR, KEEFE KA, GAUDA EB: Di and Di dopaminereceptor function in the striatum: coactivation of Di-and Di-dopamine receptors on separate populations of neurons results in potentiated immediate early gene response in Di-containing neurons. J. Neurosci. (1995) 15 (12):8167–8176.
   PubMedGoogle Scholar
• GOMEZ-MANCILLA B, BOUCHER R, GAGNON C et al.: Effect of adding the Di agonist CY 208–243 to chronic bromocriptine treatment. 1: Evaluation of motor pa-rameters in relation to striatal catecholamine content and dopamine receptors. Mov. Disord. (1993) 8:144–150.
   Google Scholar
• AKA T, OZAWA M, YAMAGUCHI M, MIZUTA E, KUNO S:Combination treatment of the partial 1)2 agonist ter-guride with the Di agonist SKY 82958 in 1-methy1-4-phenyl-1, 2,3,6-tetrahydropyridinelesioned Parkinsonian cynomolgus monkeys. J. Pharmacol. Exp. Tiler. (1995) 273:309–314.
   PubMedGoogle Scholar
• BEDARD PJ, GOMEZ-MANCILLA B, BLANCHEIlE P, GAG-NON C, DI PAOLO T: Levodopa-induced dyskinesia: facts and fancy. What does the MPTP monkey model tell us? Can.J. IVeurol. Sci. (1992) 19:134–137.
   Google Scholar
• MARCONI R, LEFEBVRE-CAPARROS D, BONNET A-M et al.:Levodopa-induced dyskinesias in Parkinson's disease: phenomenology and pathophysiology. Mov. Disord. (1994) 9:2–12.
   PubMed Web of Science ®Google Scholar
• GOMEZ-MANCILLA B, BEDARD PJ: Effect of Di and 1/2agonists and antagonists on dyskinesia produced by L-DOPA in 1-methy1-4-pheny1-1,2,3,6-tetrahydropyrid-ine-treated monkeys. J. Pharmacol. Exp. Ther. (1991) 259:409–413.
   PubMedGoogle Scholar
• LEES AJ, STERN GM: Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. Neurol. Neuroswg. Psychiatr. (1981) 43:143–150.
   Google Scholar
• BEDARD PJ, DI PAOLO T, FALARDEAU P, BOUCHER R: Chronic treatment with L-dopa, but not bromocriptine Induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with PHIspiperone binding. Brain Res. (1986) 379:294–299.
   Google Scholar
• GOMEZ-MANCILLA B, BEDARD PJ: Effect of chronic treat-ment with (+)-PIINO, a 132 agonist in MPTP-treated monkeys. Exp. Neurol. (1992) 117:185–188.
   PubMedGoogle Scholar
• LUQUIN MR, LAGUNA J, OBESO JA: Selective 132 receptor stimulation induces dyskinesia in parkinsonian mon-keys. Ann. Neurol. (1992) 31:551–554.
   PubMed Web of Science ®Google Scholar
• KREISS DS, ANDERSON LA, WALTERS JR: Apomorphine and dopamine Di receptor agonists increase the firing rates of subthalamic neurons. Neuroscience (1996) 72:863–876.
   PubMedGoogle Scholar
• CROSSMAN AR: An hypothesis on the pathophysiologi-cal mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: im-plications for future strategies in treatment. Mov. Disord. (1990) 5:100–108.
   PubMedGoogle Scholar
• PEARCE RKB, BANERJI T, JACKSON M, JENNER P, MARSDEN CD: Cholinergic manipulation of L-DOPA-induced cho-rea and dystonia in the MPTP-treated com-mon marmo-set. Mov. Disord. (1996) 11\(Suppl. 1):200.
   Google Scholar
• ASIN KE, WIRTSHAFTER D: Effects of repeated Di recep-tor stimulation on rotation and c-fos expression. Eur.J. Pharmacol. (1993) 235:167–168.
   PubMedGoogle Scholar
• GOETZ CG, TANNER CM, KLAWANS HL: Bupropion in Parkinson's disease. Neurology (1984) 34:1092–1094.
   PubMedGoogle Scholar
• DELWAIDE PJ, MARIINELLI P, SCHOENEN J: Mazindol in the treatment of Parkinson's disease. Arch. Neurol. (1983) 40:788–790.
   PubMedGoogle Scholar
• FITZGERALD PM, JANKOVIC J: Nondopaminergk ther-apy in Parkinson's disease. In: Therapy of Parkinson's Disease. Koller WC, Paulson G (Eds.), Marcel Dekker, New York (1990):369–397.
   Google Scholar
• LANG AE: Treatment of Parkinson's disease with otherthan levodopa and dopamine agonists: controversies and new approaches. Can. J. Neurol. Sci. (1984) 11:210–220.
   PubMedGoogle Scholar
• PEARCE RKB, BANERJI T, SCHEEL-KRUGER J, JENNER P: The dopamine reuptake blocker NS-2214 increases lo-comotor activity but does not produce dyskinesias in MPTP-treated common marmosets. Br. J. Pharmacol. (1995) 116(Suppl.):304
   Google Scholar
• MERCURI NB, CALABRESI P, BERNARDI G: Actions of levodopa on rat substantia nigra zona compacta neu-rons. Neurochem. Int. (1992) 20(Suppl.):2075-209S.
   Google Scholar
• BERRETTA S, ROBERTSON HA, GRAYBIEL AM: Neuro-chemically specialized projection neurons of the striatum respond differentially to psychomotor stimu-lants. In: Progress in Brain Research. Arbuthnon GW, Emson PC (Eds.), Elsevier (1993) 99:201–205.
   PubMedGoogle Scholar
• STEINER H, GERFEN CR: Dynorphin opioid inhibition ofcocaine-induced, Di dopamine receptor-mediated im-mediate-early gene expression in the striatum. J. Corn. Neurol. (1995) 353:200–212.
   PubMedGoogle Scholar
• AMALRIC M, KOOB GF: Functionally selective neuro-chemical afferents and efferents of the mesocortkolim-bic and nigrostriatal dopamine system. In: Progress in Brain Research. Arbuthnott GW, Emson PC (Eds.), Elsevier (1993) 99:209–226.
   PubMedGoogle Scholar
• XU M, HU X-T, COOPER DC, MORATELLA R et al.: Elimi-nation of cocaine-induced hyperactivity and dopamine-mediated neurophysiological effects in dopamine Di receptor mutant mice. Cell (1994) 79:945–955.
   PubMedGoogle Scholar
• ROSENZWEIG-LIPSON S, HESTERBERG P, BERCRMAN J: Observational studies of dopamine Di and D2 agonists in squirrel monkeys. Psychopharmacology (1994) 116:9–18.
   PubMedGoogle Scholar